Skip to main content

Table 4 Postdosimetric parameters (hormone-naïve, monotherapy: n = 103)

From: Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

 

Bounce (-) (n=74)

Bounce (+) (n=29)

P value

(mean ± SD)

(mean ± SD)

(t-test)

Age (year)

68.8 ± 6.1

66.1 ± 7.7

0.060

PV at postdosimetry (mL)

27.9 ± 8.0

30.8 ± 8.2

0.109

%D90 (%)

110.1 ± 10.4

112.1 ± 8.0

0.338

D90 (Gy)

167.6 ± 17.6

164.3 ± 12.5

0.360

V100 (%)

93.6 ± 3.8

94.4 ± 2.7

0.272

V150 (%)

62.7 ± 8.9

65.5 ± 8.8

0.163

R100 (mL)

0.10 ± 0.20

0.10 ± 0.10

0.936

Urethral volume (mL)

0.55 ± 0.26

0.42 ± 0.23

0.019

%UD90 (%)

95.6 ± 12.1

104.7 ± 11.3

0.001

UD90 (Gy)

145.3 ± 18.2

153.3 ± 16.2

0.041

%UD30 (%)

140.2 ± 16.1

151.5 ± 21.8

0.005

Minimal urethral dose (Gy)

107.5 ± 19.3

119.1 ± 16.6

0.006

BED (Gy2)

177.5 ± 19.7

173.7 ± 13.9

0.354